Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Humana's "Rifle Shot" At DTC

This article was originally published in RPM Report

Executive Summary

A little noticed provision of the Medicare Part D rules requires plans to sent a monthly statement to beneficiaries. Humana plans to take advantage of that communication to educate enrollees about how to save money by choosing lower-priced drugs.

You may also be interested in...



"Dollars for Donuts" Deal Revisited: What Pharma Got

A Kaiser Family Foundation report on the impact of the Medicare Part D donut hole reads like an artifact of history. But it helps quantify the benefit to brand name industry from closing the donut hole in the context of health care reform.

Drug Selection for the Masses

The Agency for Healthcare Research & Quality recently started translating evidence-based ratings of drugs into language consumers can use. The consumer guides are supposed to stimulate better discussions between patients and doctors about drug therapy. Can they drive therapeutic substitution as well?

Drug Selection for the Masses

The Agency for Healthcare Research & Quality recently started translating evidence-based ratings of drugs into language consumers can use. The consumer guides are supposed to stimulate better discussions between patients and doctors about drug therapy. Can they drive therapeutic substitution as well?

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080017

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel